GlassScriptPhysician profile
Joseph A Rose
NPI 1336901594
$1,578.73
in general payments reported to CMS, 2019-2025
21 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $326 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $253.43 | 2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $199.30 | 2025 | Provenge |
| Endo USA, INC. | $139.21 | 2025 | Xiaflex |
| Janssen Biotech, INC. | $126.68 | 2025 | Erleada |
| Janssen Pharmaceuticals, INC | $118.33 | 2024 | Spravato |
| Pfizer INC. | $105.79 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.22 | 2025 | |
| Merck Sharp & Dohme LLC | $84.43 | 2025 | Lynparza, Keytruda |
| Abbvie INC. | $60.07 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $59.23 | 2024-2025 | Lynparza, Airsupra |
| Novartis Pharmaceuticals Corporation | $45.65 | 2025 | |
| Myriad Genetic Laboratories, INC. | $43.85 | 2025 | Prolaris |
| Novo Nordisk INC | $43.40 | 2024 | Rybelsus |
| Antares Pharma, INC. | $40.20 | 2025 | Xyosted |
| Lilly USA, LLC | $36.49 | 2024 | Mounjaro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $27.47 | 2024 | Yupelri |
| Immunitybio, INC. | $21.75 | 2025 | |
| Caris Mpi, INC. | $19.36 | 2025 | Mi Cancer Seek |
| Teleflex LLC | $17.85 | 2025 | Barrigel |
| Sun Pharmaceutical Industries INC. | $17.35 | 2025 | |
| Tolmar, INC. | $16.67 | 2025 | Eligard, Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.